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Haemophilus influenza b (Hib) conjugate vaccines are
highly immunogenic in infants, as >95% develop protec-
tive antibody levels after 2 or 3 doses; hence invasive
Hib disease is now uncommon in vaccinated children.
The precise protective level is not clearly established,
although a titre of 1 μg/mL is considered to offer long-
term protection. Hib vaccination above the age of 5 is
not recommended; the majority of older even unvacci-
nated children seem to be immune to Hib, probably
from asymptomatic infections in infancy. The vaccine
though is used in any age as a functional assay of the
responsiveness of the immune system to capsular
polysaccharide antigens, We present 3 children with
recurrent upper respiratory tract infections where the
test vaccine has also acted in a therapeutic manner.
1) A 6 yr old boy was referred to us for urticaria. His
mother mentioned frequent “colds” requiring antibiotics
several times a year. His serum Immunoglobulins and rou-
tine investigations were normal/negative except for the
functional Hib antibody levels which were suboptimal at
0.22 μg/mL rising to >10 μg/mL 4 weeks post-vaccination,
when the recurrent infections stopped.
2) Another 6 yr old was referred with eczema and the
mother mentioned that he had been investigated inconclu-
sively for unexplained lethargy. He was blowing green
mucus from his “constantly blocked nose”; his functional
Hib antibody levels were suboptimal at <0.15 rising even-
tually to 1.7 μg/mL after 3 vaccinations, which stopped the
subclinical sinusitis and of course the lethargy.
3) A third child was seen for nut allergy. He missed
his follow-up appointments for 18 months because he
was constantly having respiratory infections, which
caused bronchiectasis. A sputum sample at the time of
the diagnosis grew Haemophilus (not typed) and started
prophylactic antibiotics. A blood test a month later
showed suboptimal levels of functional antibody and
subsequently excellent response to the vaccination; the
infections stopped, although one could argue this was
an effect of the prophylactic antibiotics.
Our relevant adult and paediatric data is currently being
studied and processed as this is a new therapeutic aspect.
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